Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 109

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 109
---
 and to pursue new market opportunities that develop as a result of technological and scientific advances. We must continually update our offerings to reflect new scientific knowledge about genes and genetic variations and their role in diseases and treatment therapies, or else our tests could become obsolete or not cost -effectiveand our business adversely affected. In addition, our entry into the pharmacogenetic testing markets expose us to increased liability. Errors or mistakes in interpreting test results could have a significant adverse impact on our business, results of operations, financial condition and growth prospects, as we may be subject to liability for errors, misunderstandings, or inappropriate reliance on information we provide to clinicians, geneticists or patients. We maintain liability insurance, but this may not fully protect us from financial impact, injury to our reputation, or suspension of sales of our tests. The sizes of the markets and forecasts of market growth for the demand of our products and services, including our research services and other key potential success factors are based on a number of complex assumptions and estimates, and may ultimately be inaccurate. We estimate annual total addressable markets and forecasts of market growth for our services. We have also developed a standard set of key performance indicators in order to enable us to assess the performance of our business in and across multiple markets, and to forecast future revenue. These estimates, forecasts and key performance indicators are based on a number of complex assumptions, internal and third -partyestimates and other business data, including assumptions and estimates relating to our ability to generate revenue from the development of new workflows. While we believe our assumptions and the data underlying our estimates and key performance indicators are reasonable, there are inherent challenges in measuring or forecasting such information. As a result, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors and indicators. Consequently, our estimates of the annual total addressable market and our forecasts of market growth and future revenue from our products and services, including our research services may prove to be incorrect, and our key business metrics may not reflect our actual performance. For example, if the annual total addressable market or the potential market growth for our products and services is smaller than we have estimated or if the key business metrics we utilize to forecast revenue are inaccurate, it may impair our sales growth and have an adverse impact on our business, financial condition, results of operations and growth prospects. 29 We have a history of losses, and we may not be able to achieve or sustain profitability. The Company has historically incurred